Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 8, 2006, Pages 2154-2157

  Tilloy, Sébastien ^a   Monnaert, Véronique ^a   Fenart, Laurence ^a   Bricout, Hervé ^a   Cecchelli, Roméo ^a   Monflier, Eric ^a  

^a UNIVERSITÉ D'ARTOIS   (France)

Author keywords

Blood brain barrier; Cholesterol; Cyclodextrin; Doxorubicin; P glycoprotein

Indexed keywords

BETA CYCLODEXTRIN; CHOLESTEROL; DOXORUBICIN; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CHOLESTEROL SYNTHESIS; COCULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; ENDOTHELIUM CELL; IN VITRO STUDY; NEUROMODULATION; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; BLOOD-BRAIN BARRIER; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOTHELIAL CELLS; METHYLATION; P-GLYCOPROTEINS; RATS;

ANIMALIA;

EID: 33644797560     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.01.049     Document Type: Article

References (26)

1. W. Pardrige Mol. Interv. 100 2003 90
2. T. Ohnishi, I. Tamai, K. Sakanaka, A. Sakata, T. Yamashima, J. Yamashita, and A. Tsuji Biochem. Pharmacol. 17 1995 1541
3. J. Huwyler, D. Wu, and W.M. Pardridge Proc. Natl. Acad. Sci. 93 1996 14164
4. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin J. Drug Target. 10 2002 317
5. C. Rousselle, M. Smirnova, P. Clair, J.M. Lefauconnier, A. Chavanieu, B. Calas, J.M. Scherrmann, and J. Temsamani J. Pharmacol. Exp. Ther. 296 2001 124
6. L. Fenart, V. Buee-Scherrer, L. Descamps, C. Duhem, M.G. Poullain, R. Cecchelli, and M.P. Dehouck Pharm. Res. 15 1998 993
7. E.A. Neuwelt, M. Pagel, P. Barnett, M. Glassberg, and E.P. Frenkel Cancer Res. 41 1981 4466
8. V. Monnaert, S. Tilloy, H. Bricout, L. Fenart, R. Cecchelli, and E. Monflier J. Pharmacol. Exp. Ther. 310 2004 745
9. O. Bekers, J.H. Beijnen, M. Otagiri, A. Bult, and W.J.M. Underberg J. Pharm. Biomed. Anal. 8 1990 671
10. V. Monnaert, D. Betbeder, L. Fenart, H. Bricout, A.M. Lenfant, C. Landry, R. Cecchelli, E. Monflier, and S. Tilloy J. Pharmacol. Exp. Ther. 311 2004 1115
11. R. Cecchelli, B. Dehouck, L. Descamps, L. Fenart, V. Buee-Scherrer, C. Duhem, S. Lundquist, M. Rentfel, G. Torpier, and M.P. Dehouck Adv. Drug Del. Rev. 36 1999 165
12. For further information on the in vitro model of BBB, see: M.P. Dehouck, P. Jolliet-Riant, F. Brée, J.C. Fruchart, R. Cecchelli, and J.P. Tillement J. Neurochem. 58 1992 1790
13. 3H]inulin in each compartment was determined with a liquid scintillation counter (Tri-Carb 2100TR).
14. 14C]doxorubicin in each compartment was determined with a liquid scintillation counter (Tri-Carb 2100TR).
15. 3H]vincristine in each compartment were determined with a liquid scintillation counter (Tri-Carb 2100TR).
16. 3H]vincristine, respectively.
17. J. Jodoin, M. Demeule, L. Fenart, R. Cecchelli, S. Farmer, K.J. Linton, C.F. Higgins, and R. Beliveau J. Neurochem. 87 2003 1010
18. P.W. Shaul, and R.G.W. Anderson Am. J. Physiol. 275 1998 L843
19. 3H]cholesterol in BCEC in the presence and in the absence (control) of CDs after 2 h of experiment was determined in a liquid scintillation counter (Tri-Carb 2100TR). Results are expressed as a percentage of the total cholesterol released from BCEC in the presence of CD compared to the control.
20. H.W. Frijlink, A.C. Eissens, N.R. Helfting, K. Poelstra, C.F. Lerk, and D.K.F. Meijer Pharm. Res. 8 1991 9
21. J. Nishijo, S. Moriyama, and S. Shiota Chem. Pharm. Bull. 51 2003 1253
22. E.P.C. Kilsdonk, P.G. Yancey, G.W. Stoudt, F.W. Bangerter, W.J. Johnson, M.C. Phillips, and G.H. Rothblat J. Biol. Chem. 270 1995 17250
23. H. Arima, K. Yunomae, F. Hirayama, and K. Uekama J. Pharmacol. Exp. Ther. 297 2001 547
24. K. Yunomae, H. Arima, F. Hirayama, and K. Uekama FEBS Lett. 536 2003 225
25. S.W. Kamau, S.D. Kramer, M. Gunther, and H. Wunderli-Allenspach In vitro Cell. Dev. Biol. Anim. 41 2005 207
26. S. Cisternino, C. Rousselle, C. Dagenais, and J.M. Schermann Pharm. Res. 18 2001 183